|
 Bind's shares fell 15 percent to $10.95 in extended trading on
Wednesday. Angen's shares were little changed from their close of
$121.03.
"Despite achieving the objective of high tumor concentrations, the
results were not sufficiently compelling to proceed forward and both
collaborators have agreed that the program will not be continued,"
Bind's Chief Executive Scott Minick said in a statement.
The company had entered into a twelve-month collaboration agreement
with Amgen in January 2013 to develop cancer treatments using Bind's
nanotechnology platform and an Amgen compound.
(Reporting By Anjalirao Koppala in Bangalore; Editing by Savio
D'Souza)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
